Natural killer cells surrounding leukaemia blast cells in glowing bone marrow, representing NK cell therapy for blood cancers at VELAR Center Bangkok

NK cell therapy for leukaemia and lymphoma is an investigational form of adoptive immunotherapy in which natural killer cells — from the patient, a donor, cord blood or a stem-cell line — are expanded in a laboratory and infused to attack blood cancer cells. Blood cancers are where NK-cell therapy has its strongest human data, and even there the field is still dominated by early-phase trials rather than approved products.

Why blood cancers came first. Leukaemia and lymphoma cells circulate in blood, marrow and lymphoid tissue, so an infused NK cell does not have to cross a dense tumour stroma to meet its target. That single anatomical fact explains most of the gap between haematologic and solid-tumour results.

The founding observation is transplant biology. Long before anyone manufactured NK cells as a product, transplant physicians noticed that certain donor–recipient mismatches produced fewer leukaemia relapses [1]. That clue is still the intellectual backbone of the field.

What this article does. It separates what is mechanistically plausible, what has been observed in patients, and what remains unproven — because in blood-cancer immunotherapy those three categories are frequently blurred in marketing language.

Clinical status in one line. As of 2026, no NK-cell product is an approved standard-of-care treatment for leukaemia or lymphoma in Thailand, the United States or the European Union; access is through clinical trials or regulated compassionate/named-patient pathways. Treatment decisions for blood cancer should be made with a haematologist or haemato-oncologist.

How natural killer cells recognise leukaemia and lymphoma cells

NK cells kill without prior sensitisation, using a balance of activating and inhibitory receptors rather than a single antigen-specific receptor [2]. This is the core difference from T cells, and it matters enormously in blood cancers.

Missing-self recognition. Inhibitory killer-cell immunoglobulin-like receptors (KIR) read HLA class I molecules on a target cell. Malignant cells that downregulate HLA class I — a common immune-escape strategy — become less able to switch NK cells off, a principle first demonstrated in lymphoma models in the 1980s [3].

Stress-ligand recognition. Transformed cells also upregulate stress ligands such as MICA/MICB and ULBPs that engage the activating receptor NKG2D, and ligands for NKp30, NKp44 and NKp46 [4]. Killing follows when activating signals outweigh inhibitory ones.

Antibody-dependent killing. Through CD16 (FcγRIIIa), NK cells also execute antibody-dependent cellular cytotoxicity — the mechanism that partly underlies rituximab activity in B-cell lymphoma and that many NK combination protocols try to exploit [5].

The transplant evidence: donor NK alloreactivity and leukaemia relapse

The strongest historical signal for NK activity against leukaemia comes from haploidentical stem-cell transplantation, not from infused NK products. In a landmark analysis, acute myeloid leukaemia patients transplanted from donors whose NK cells were predicted to be alloreactive — because the recipient lacked the HLA ligand for a donor inhibitory KIR — had markedly lower relapse rates [1].

Two immune cells facing each other with surface receptors failing to engage, illustrating KIR–HLA mismatch that licenses donor NK cells to attack leukaemia

How to read that result honestly. It is retrospective donor-selection data from a transplant setting with lymphodepletion, engraftment and graft-versus-leukaemia effects operating together. It establishes that NK biology influences leukaemia control; it does not establish that an infused NK product reproduces that effect [6].

Why the distinction matters to patients. Clinics sometimes cite transplant relapse data as though it were evidence for an outpatient NK infusion. The biology is shared; the clinical context is not.

What adoptive NK cell infusion trials have shown in leukaemia

Adoptive transfer of haploidentical NK cells with lymphodepleting chemotherapy can produce in-vivo expansion and complete remissions in a minority of patients with refractory acute myeloid leukaemia. In the foundational study, a subset of poor-prognosis AML patients achieved complete remission after NK infusion supported by interleukin-2 [7].

Regulatory T cells were a limiting factor. A later trial adding an IL-2 diphtheria-toxin fusion protein to deplete regulatory T cells improved NK expansion and remission rates compared with historical controls [8]. This is a recurring theme: the host environment, not just the product, determines what the cells can do.

Paediatric feasibility. A pilot study in children with AML in first complete remission showed that haploidentical NK infusion after immunosuppressive conditioning was feasible and tolerable, with no graft-versus-host disease attributed to the NK product [9].

Expanded and cytokine-supported products. Trials using membrane-bound IL-21-expanded donor NK cells after haploidentical transplant, and recombinant IL-15 support, have reported feasibility with distinct toxicity profiles — including a cytokine-release signal with systemic IL-15 [10][11].

Myelodysplastic syndrome and high-risk clones. A Swedish study reported complete remissions with reduction of high-risk clones in some patients with MDS and AML after haploidentical NK-cell therapy, while emphasising the small sample size [12].

Memory-like NK cells: the most interesting recent development

Cytokine-induced memory-like NK cells are NK cells briefly pre-activated with IL-12, IL-15 and IL-18, which then display enhanced and durable responses when re-stimulated. In a first-in-human study, memory-like NK cells produced clinical responses in patients with relapsed or refractory AML [13].

Immune cells bathed in glowing cytokines and emerging larger and more activated, representing cytokine-induced memory-like NK cells for leukaemia

Why it matters mechanistically. Short cytokine exposure reprogrammes NK cells epigenetically and metabolically, producing longer persistence and stronger interferon-gamma responses than standard activation [14].

Where the evidence stops. Later multidimensional analyses identified donor and product features associated with response, but these are correlative findings from small cohorts, not validated predictive biomarkers [15]. No randomised trial has yet shown a survival benefit.

CAR-NK cells in lymphoma and CLL

CAR-NK cells are NK cells engineered with a chimeric antigen receptor, most often targeting CD19 for B-cell malignancies. In a phase 1/2 study of cord-blood-derived CD19 CAR-NK cells in relapsed or refractory CD19-positive lymphoid tumours, responses were seen without cytokine release syndrome, neurotoxicity or graft-versus-host disease of the severity typically associated with CAR-T therapy [16].

The larger follow-up tempered expectations. An expanded phase 1/2 report confirmed a favourable safety profile but showed that response depended strongly on disease type, prior therapy and product characteristics, with a substantial proportion of patients not responding [17].

Off-the-shelf logic. Because NK cells do not cause classical graft-versus-host disease, allogeneic and iPSC-derived products can in principle be manufactured in advance and banked — the main practical argument for NK over autologous CAR-T [18].

The trade-off. NK cells persist for days to weeks rather than years, so durability is the field's central unsolved problem. If you want the receptor-level comparison, see our explainer on NK cell therapy versus CAR-T.

Which blood cancers are actually being studied

NK-cell trials in haematology are concentrated in a small number of diagnoses, and the depth of evidence differs sharply between them. Grouping them all as "blood cancer" hides that difference.

DiseaseTypical NK approach studiedDepth of evidence
Acute myeloid leukaemia (AML)Haploidentical NK infusion, memory-like NK, post-transplant NKMost developed; several phase 1/2 trials with remissions reported [7][13]
Myelodysplastic syndrome (MDS)Haploidentical NK infusionSmall cohorts, some clonal reduction reported [12]
B-cell lymphoma / CLLCD19 CAR-NK, ADCC combinationsPhase 1/2 with response and safety data, non-responders common [16][17]
Acute lymphoblastic leukaemia (ALL)CAR-NK, donor NK after transplantEarlier stage; less published NK-specific outcome data
Multiple myelomaNK with immunomodulatory drugs and antibodiesExploratory; combination-dependent [6]

Read the table as a map of research activity, not of effectiveness. A disease appearing in more trials means more investigators think the biology is plausible — it does not mean the treatment works for that diagnosis.

Relapsed and refractory disease dominates. Nearly all participants in these studies had already failed standard therapy, which is exactly why response rates cannot be generalised to newly diagnosed patients.

What an NK-cell protocol actually involves

An NK-cell trial is a multi-week clinical process, not a single appointment, and understanding the sequence makes the risks legible.

  1. Eligibility and disease assessment. Marrow biopsy, cytogenetics, molecular markers and performance status determine whether a patient can safely be enrolled.
  2. Cell sourcing. Apheresis from a haploidentical donor, a cord-blood unit, or an established cell line — each with different HLA and KIR implications [1].
  3. Manufacturing. Selection, expansion (often with IL-2, IL-15 or membrane-bound IL-21 feeder systems) and release testing for purity, viability, sterility and residual T cells [10].
  4. Lymphodepleting conditioning. Usually fludarabine with cyclophosphamide, to reduce competing lymphocytes and create cytokine space for the infused cells [7].
  5. Infusion and cytokine support. IL-2 or IL-15 may be given to support in-vivo expansion, with its own toxicity profile [11].
  6. Monitoring and response assessment. Counts, chimerism, persistence assays and marrow re-evaluation at protocol-defined intervals.

The conditioning step is the one patients underestimate. It is genuine chemotherapy with genuine risk of cytopenias and infection, and it is the reason a serious NK protocol belongs in a haematology unit rather than a wellness clinic.

Safety in blood-cancer settings

NK-cell products have so far shown a different and generally milder toxicity profile than CAR-T cells, but "milder" is not "safe by default". Most serious events in these trials come from the conditioning chemotherapy and cytokine support rather than the NK cells themselves.

Safety details are covered further in our article on NK cell therapy safety and side effects.

Honest limitations

The limitations here are structural, not cosmetic, and they apply to every clinic offering NK cells for blood cancer.

  1. Almost all data are phase 1/2. Single-arm early-phase trials cannot separate treatment effect from patient selection.
  2. Persistence is short. Without cytokine support, infused NK cells are often undetectable within weeks [7].
  3. Products are not interchangeable. Source, expansion method, dose and cryopreservation status differ so much between trials that cross-study comparison is unreliable [6].
  4. Response predictors are unvalidated. KIR-ligand mismatch, NK dose and product phenotype are associated with outcome in some studies and not others [15].
  5. Context cannot be transplanted. Results obtained with intensive conditioning in a transplant unit do not transfer to a standalone outpatient infusion.
Medical disclaimer. This article is educational and does not constitute medical advice, diagnosis or a treatment recommendation. NK cell therapy for leukaemia and lymphoma is investigational. Standard treatment — chemotherapy, targeted agents, immunotherapy, stem-cell transplantation — should not be delayed, stopped or replaced on the basis of this article. Discuss any cell-therapy option with your treating haematologist.

Questions to ask before considering NK cell therapy for a blood cancer

These questions separate a regulated research pathway from an unaccountable commercial offer.

Frequently asked questions

Is NK cell therapy an approved treatment for leukaemia?

No. NK-cell products remain investigational for leukaemia and lymphoma and are not approved standard therapy in Thailand, the US or the EU. Access is normally through clinical trials.

Does NK cell therapy work better in blood cancers than in solid tumours?

The available human data are stronger in blood cancers, largely because circulating malignant cells are physically accessible to infused NK cells. That is a relative statement about evidence, not proof of efficacy.

How is NK cell therapy different from CAR-T therapy?

CAR-T cells are usually autologous, persist for months to years and carry a higher risk of severe cytokine release syndrome and neurotoxicity. NK cells can be allogeneic and off-the-shelf with a milder toxicity signal, but persist far more briefly [16].

Can NK cell therapy replace chemotherapy or transplantation?

No. In every published trial NK cells were given alongside or after standard treatment, most often with lymphodepleting conditioning, and never as a validated replacement for curative-intent therapy.

Why do trial results vary so much between centres?

Because the products differ. Cell source, expansion cytokines, dose, purity, fresh-versus-cryopreserved delivery and conditioning regimen all change what is actually infused [6].

What should a patient in Bangkok do with this information?

Keep the haematologist in charge of the cancer treatment plan, ask whether a registered trial exists for the specific diagnosis, and treat any clinic promising remission from an NK infusion alone as a red flag.

References

  1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. doi:10.1126/science.1068440 ↩
  2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nature Immunology. 2008;9(5):503-510. doi:10.1038/ni1582 ↩
  3. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675-678. doi:10.1038/319675a0 ↩
  4. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nature Immunology. 2016;17(9):1025-1036. doi:10.1038/ni.3518 ↩
  5. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in Immunology. 2015;6:368. doi:10.3389/fimmu.2015.00368 ↩
  6. Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nature Reviews Clinical Oncology. 2021;18(2):85-100. doi:10.1038/s41571-020-0426-7 ↩
  7. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057. doi:10.1182/blood-2004-07-2974 ↩
  8. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014;123(25):3855-3863. doi:10.1182/blood-2013-10-532531 ↩
  9. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of Clinical Oncology. 2010;28(6):955-959. doi:10.1200/JCO.2009.24.4590 ↩
  10. Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857-1868. doi:10.1182/blood-2017-05-785659 ↩
  11. Cooley S, He F, Bachanova V, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. Blood Advances. 2019;3(13):1970-1980. doi:10.1182/bloodadvances.2018028332 ↩
  12. Björklund AT, Carlsten M, Sohlberg E, et al. Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clinical Cancer Research. 2018;24(8):1834-1844. doi:10.1158/1078-0432.CCR-17-3196 ↩
  13. Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine. 2016;8(357):357ra123. doi:10.1126/scitranslmed.aaf2341 ↩
  14. Gang M, Wong P, Berrien-Elliott MM, Fehniger TA. Memory-like natural killer cells for cancer immunotherapy. Seminars in Hematology. 2020;57(4):185-193. doi:10.1053/j.seminhematol.2020.11.003 ↩
  15. Berrien-Elliott MM, Cashen AF, Cubitt CC, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discovery. 2020;10(12):1854-1871. doi:10.1158/2159-8290.CD-20-0312 ↩
  16. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New England Journal of Medicine. 2020;382(6):545-553. doi:10.1056/NEJMoa1910607 ↩
  17. Marin D, Li Y, Basar R, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nature Medicine. 2024;30(3):772-784. doi:10.1038/s41591-023-02785-8 ↩
  18. Cichocki F, Bjordahl R, Gaidarova S, et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Science Translational Medicine. 2020;12(568):eaaz5618. doi:10.1126/scitranslmed.aaz5618 ↩
  19. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758 ↩